Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher L Corless

Showing results (181-190 of 208) with videos related to

Pageof 21
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinasesMichael C Heinrich, Heikki Joensuu, George D Demetri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2011
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplificationJun Guo, Lu Si, Yan Kong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failureGeorge D Demetri, Michael C Heinrich, Jonathan A Fletcher, et al.
Journal of Translational Medicine|December 16, 2018
Implementing a comprehensive translational oncology platform: from molecular testing to actionabilityZahi I Mitri, Swapnil Parmar, Brett Johnson, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 13, 2006
A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cellsRobert B West, Brian P Rubin, Melinda A Miller, et al.
Histopathology|January 30, 2020
Recurrent RET gene fusions in paediatric spindle mesenchymal neoplasmsJessica L Davis, Sara O Vargas, Erin R Rudzinski, et al.
NPJ Precision Oncology|March 27, 2021
Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analyticsAllen Li, Jamie M Keck, Swapnil Parmar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2012
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trialSuzanne George, Qian Wang, Michael C Heinrich, et al.
The American Journal of Surgical Pathology|January 29, 2008
A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumorsInigo Espinosa, Cheng-Han Lee, Mi Kyung Kim, et al.
Oncogene|August 25, 2004
Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profilesSubbaya Subramanian, Robert B West, Christopher L Corless, et al.
Pageof 21

Showing results (181-190 of 208) with videos related to

Sort By:
Pageof 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinasesMichael C Heinrich, Heikki Joensuu, George D Demetri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2011
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplificationJun Guo, Lu Si, Yan Kong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failureGeorge D Demetri, Michael C Heinrich, Jonathan A Fletcher, et al.
Journal of Translational Medicine|December 16, 2018
Implementing a comprehensive translational oncology platform: from molecular testing to actionabilityZahi I Mitri, Swapnil Parmar, Brett Johnson, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 13, 2006
A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cellsRobert B West, Brian P Rubin, Melinda A Miller, et al.
Histopathology|January 30, 2020
Recurrent RET gene fusions in paediatric spindle mesenchymal neoplasmsJessica L Davis, Sara O Vargas, Erin R Rudzinski, et al.
NPJ Precision Oncology|March 27, 2021
Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analyticsAllen Li, Jamie M Keck, Swapnil Parmar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2012
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trialSuzanne George, Qian Wang, Michael C Heinrich, et al.
The American Journal of Surgical Pathology|January 29, 2008
A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumorsInigo Espinosa, Cheng-Han Lee, Mi Kyung Kim, et al.
Oncogene|August 25, 2004
Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profilesSubbaya Subramanian, Robert B West, Christopher L Corless, et al.
Pageof 21